Understand the source comparison
SS-LUP-332 Side Effects Long Term Research: Comparison Across PPARδ Compounds
SS-LUP-332 (SLU-PP-332) PPARδ partial agonist (40–60% activation) 30–40% at therapeutic doses (mild-moderate nausea, diarrhea) Liver enzyme elevation in 8–12% at >15mg daily; reversible with dose reduction Triglycerides ↓15–25%, LDL ↑10–20mg/dL in 15–20% of pa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332 (SLU-PP-332)
- PPARδ partial agonist (40–60% activation)
- 30–40% at therapeutic doses (mild-moderate nausea, diarrhea)
- Liver enzyme elevation in 8–12% at >15mg daily; reversible with dose reduction
- Triglycerides ↓15–25%, LDL ↑10–20mg/dL in 15–20% of participants
- No. Longest human trial is 12 weeks (Phase 1 completed 2024)
- Promising short-term metabolic effects but insufficient exposure duration to assess chronic hepatic, cardiovascular, or oncogenic risk. Ongoing Phase 2 trials target 24-week endpoints.
- GW501516 (Cardarine)
- PPARδ full agonist
- 20–30% (primarily nausea during titration)
- Severe. Dose-dependent hepatotoxicity and tumour promotion in rodent models led to trial termination
- Triglycerides ↓20–30%, HDL ↑10–15%, LDL variable
- Yes. Terminated in Phase 2 after 18–24 month rodent toxicity studies
- Abandoned due to cancer risk in animal models. Despite strong metabolic effects, long-term safety concerns outweighed therapeutic benefits. Not approved for human use.
- MBX-8025 (Seladelpar)
- PPARδ selective modulator
- 15–25% (mild GI disturbances)
- Moderate. Transient ALT/AST elevation in 10–15% of participants
- Triglycerides ↓25–35%, HDL ↑5–10%, LDL stable or slight decrease
- Yes. Phase 2 trials extended to 52 weeks; FDA hold issued 2019 due to liver safety signals
- More selective than full agonists but still triggered hepatic safety concerns in extended trials. Development paused pending additional long-term hepatic monitoring data.
- Fenofibrate
- PPARα agonist (different receptor subtype)
- 5–10% (minimal GI effects)
- Rare. Hepatotoxicity <1% in long-term use
- Triglycerides ↓30–50%, HDL ↑10–20%, LDL variable (may increase in some patients)
- Yes. Approved since 1975; decades of post-marketing surveillance data
- Different mechanism (PPARα vs PPARδ) but demonstrates that PPAR modulation can be used safely long-term with appropriate monitoring. Not directly comparable to SS-LUP-332's metabolic profile.
- The comparison underscores a critical point: ss-lup-332 side effects long term research is not hypothetical risk assessment. It's extrapolation from compounds with similar mechanisms that have already shown dose-limiting toxicity in extended exposure. SS-LUP-332's partial agonism may reduce risk, but 'reduced risk' is not 'no risk' until proven across 18–36 month human trials.